Clinical trials: Older Adults With Cancer
Acute Myeloid Leukemia (AML)
Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors
The purpose of this study is to test a method of bone marrow transplantation that results in only temporary donor immune function.
- Trial name
- NCT02519712
- Testing
- Induction Chemotherapy, G-PBSC Infusion
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B-Cell Lymphoma
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
This is a single-arm, Phase II study designed to enroll and treat up to 64 patients. All patients in this study will receive ofatumumab and bendamustine as an IV infusion for 6 cycles (a cycle is defined as 21 days in length).
- Trial name
- NCT01626352
- Testing
- Bendamustine, Ofatumumab
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- SCRI Development Innovations, LLC
Acute Myeloid Leukemia
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid…
- Trial name
- NCT06317649
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 229 sites in United States, Canada and 1 more
- Volunteers
- 147 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer Stage III
Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer
Concurrent chemoradiotherapy without disease progression followed by consolidation durvalumab is standard of care for unresectable, stage III non-small-cell lung cancer (NSCLC) (the 'PACIFIC regimen').
- Trial name
- NCT05557552
- Testing
- standar thoracic RT dose, decreased thoracic RT dose
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Ruijin Hospital
Stage III Non-small-cell Lung Cancer
Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC
Elderly (age 70 years or older) or >18 years old AND poor risk (ECOG 2) newly diagnosed stage IIIA-C (AJCC 8th edition) inoperable non-small cell lung cancer (NSCLC) patients are eligible to participate in this phase II open…
- Trial name
- ESR1814205 (NCT04441138)
- Testing
- Durvalumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rush University Medical Center
Acute Myeloid Leukemia
Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients
A phase II trial to compare the efficacy and safety of nivolumab and intermediate dose cytarabine with or without haploidentical lymphocyte infusion.
- Trial name
- NCT03381118
- Testing
- Cytarabine, Nivolumab, G-CSF mobilized HLA-haploidentical donor PBSC
- Where
- Russia
- Volunteers
- 16 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly
This is a prospective phase II, single-arm clinical study that plans to enroll 45 patients aged 60 years or older with primary AML diagnosed after April 1, 2023.The purpose of this trial is to evaluate the efficacy of Venetoclax…
- Trial name
- NCT05949762
- Testing
- Venetoclax in Combination With Azacitidine and HA Regimen
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- ZePing Zhou
Hodgkin Lymphoma
Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients
The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.
- Trial name
- AVD-Rev (NCT01056679)
- Testing
- Doxorubicine, DTIC, Lenalidomide
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University of Cologne
Leukemia, Myeloid, Acute, De Novo
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
A phase I-II trial based on the combination of three drugs regimen LDAC or Azacitidine + Venetoclax + Quizartinib that in this population could be well tolerated by a sequential type administration.
- Conditions
- Leukemia, Myeloid, Acute, De Novo, Age More 60yr
- Trial name
- NCT04687761
- Testing
- Azacitidine, Venetoclax, Quizartinib
- Where
- 15 sites in Spain
- Volunteers
- 113 people
- Sponsor
- PETHEMA Foundation
Cognitive Impairment, Hematologic Malignancies
Cognitive Impairment in Older Adults With Hematologic Malignancies
This cross-sectional study aims to determine the prevalence of cognitive impairment and evaluate its relationship with activities of daily living among older adults with hematologic malignancies receiving chemotherapy.
- Conditions
- Cognitive Impairment, Hematologic Malignancies, Chemotherapy Effect
- Trial name
- NCT07842679
- Volunteers
- 120 people
- Sponsor
- Assiut University
Diffuse Large B Cell Lymphoma
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
This is a single-arm, open-label phase 2 study of iR2 in the treatment of unfit and elderly patients with untreated diffuse large B-cell lymphoma。
- Trial name
- NCT03949062
- Testing
- Ibrutinib, Lenalidomide, Rituximab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Acute Myeloid Leukemia
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares ASTX727 with standard duration versus shorter duration of venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML).
- Trial name
- NCT07437950
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Decitabine and Cedazuridine
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 126 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00006122
- Testing
- cytarabine, etoposide, gemtuzumab ozogamicin
- Where
- 18 sites in Austria, Belgium and 5 more
- Volunteers
- 106 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Gastric Cancer, Chemotherapy Effect
Neoadjuvant Chemotherapy Plus Surgery Versus Surgery First For Elderly Gastric Cancer Patients
The main purpose of this study is to compare the feasibility and efficacy of neoadjuvant chemotherapy (modified SOX) for elderly patients with locally advanced gastric cancer.
- Conditions
- Gastric Cancer, Chemotherapy Effect, Elderly Patients, Surgery
- Trial name
- RJGC-Senile (NCT04677673)
- Testing
- Chemotherapy, Curative gastrectomy
- Volunteers
- 232 people
- Sponsor
- BIRENDRA KUMAR SAH
Mantle Cell Lymphoma (MCL)
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
This is a single- arm, open-label, multicenter, phase II study to evaluate Acalabrutinib plus Rituximab for the treatment of elderly or low- to intermediate-risk younger untreated mantle cell lymphoma
- Trial name
- NCT06846489
- Testing
- Acalabrutinib, Rituximab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00454480
- Testing
- alemtuzumab, arsenic trioxide, azacitidine
- Where
- 96 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- The University of New South Wales
Infections, Papillomavirus
Study of Natural History of Human Papillomavirus (HPV) Infections in Adult Women With Recurrent Conizations in Norway
This is a register-based, epidemiological study of HPV type distribution in women aged 18 years and above with recurrent conization following a primary conization for high grade lesions/ microinvasive carcinomas.
- Trial name
- NCT00924794
- Testing
- Cancer Registry of Norway (database)
- Where
- Norway
- Volunteers
- 410 people
- Sponsor
- GlaxoSmithKline
Advanced Non Small Cell Lung Cancer
Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients
Lung cancer is the most common cancer in the world and the leading cause of cancer-related deaths in Western countries. Unfortunately, at the time of diagnosis, the majority of patients already have metastatic disease and a…
- Trial name
- eNERGY (NCT03351361)
- Testing
- Nivolumab + Ipilimumab, Chemotherapy
- Where
- 30 sites in France
- Volunteers
- 217 people
- Sponsor
- Rennes University Hospital
Glioblastoma, Malignant Glioma
18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy
This phase II trial studies how well fluorodopa F 18-positron emission tomography/magnetic resonance imaging scan (18F-DOPA-PET/MRI) works in imaging elderly patients with newly diagnosed grade IV malignant glioma or glioblastoma…
- Trial name
- NCT03778294
- Testing
- Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Mayo Clinic
Breast Cancer
Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast
Although approximately 50% of new diagnosis breast cancers are in patients above the age of 65, elderly people remain substantially under-represented in clinical trials, and therefore are under-treated.
- Trial name
- ICE-II (NCT01204437)
- Testing
- Epirubicin, Cyclophosphamide, Cyclophosphamide, Methotrexate, 5 FU, Capecitabine, Nab-Paclitaxel
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- GBG Forschungs GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.